Fighting Prostate Cancer's Survival Mechanisms

Dr. Kim Chi (1999 Research Grant)

Cancer cells are extremely adaptable and can mutate to resist treatments. For example, cancer cells make a protein called clusterin which resists hormone therapy, radiation and other treatments. Mutations like clusterin make cancer difficult to treat.

In 1999 we awarded Dr. Kim Chi a grant to study a new clusterin-fighting drug. Called OGX-011, the drug his team developed contains genetically engineered material that inhibits the production of clusterin and leaves cancer cells vulnerable to radiation therapy.

Dr. Chi is now overseeing the clinical development of OGX-011. Early results from 72 patients were positive; the drug inhibited clustern in prostate cancer cells by more than 90 per cent. Phase II testing is now ongoing.

Donate Now!

Go Plaid. Help Dad.


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive